Results 241 to 250 of about 741,060 (264)

An Integrated Clinical-Radiomics-Deep Learning Model Based on ¹⁸F-FDG PET/CT for Predicting EGFR Mutation Status in Lung Adenocarcinoma. [PDF]

Cancer Med
Wang Y, Chen Z, Li J, Cai Y, Sun C, Zhang J, Hacker M, Li X, Yi H.   +8 more
europepmc   +1 more source

Public assistance and survival equality in patients with EGFR mutation-positive lung cancer. [PDF]

Jpn J Clin Oncol
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Tsuya A, Okabe T, Fukuoka M, Minami H.   +20 more
europepmc   +1 more source

EGFR Mutation Detection in Whole Slide Images of Non-Small Cell Lung Cancers Using a Two-Stage Deep Transfer Learning Approach. [PDF]

Cancer Med
Zanoletti M, Ugolini F, El Bachiri L, Pasini V, Laurino M, Logu F, Melissa E, Marchi C, Colombino M, Massi D, Rindi G, Comin CE, Palmieri G, Cossu A.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Journal of Oncology Pharmacy Practice, 2020
Val R Adams, Patrick Medina
exaly  

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting

Annals of Oncology, 2012
Tetsuya Mitsudomi, G Ishii
exaly  

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

Journal of Hematology and Oncology, 2015
Minglei Zhuo, Xiaomei Su, Meina Wu
exaly  

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

Journal of Thoracic Oncology, 2020
Lin Wu, Ziping Wang, Jianying Zhou
exaly  

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†

Annals of Oncology, 2015
Y-L Wu, Y Zuo
exaly  

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non–Small Cell Lung Cancer

Journal of Thoracic Oncology, 2017
Emily Feld, Emily H Castellanos
exaly